https://www.selleckchem.com/Androgen-Receptor.html
Introduction With the global incidence of ovarian cancer set to rise by 55% to 371 000 per year by 2035, current 5-year survival rates below 50%, and 15% of women with ovarian cancer dying within 2 months of diagnosis, urgent action is required to improve survival and quality of life. Objective To deal with the evidence gap relating to the experience of women with the disease around the globe and identify opportunities to drive progress. Methods The study included a review of global trends in incidence, mortality, and survival (October